Necrolytic Migratory Erythema—A Case Report of Pancreatic Occupying Lesion

HU Zhonghui; YANG Lu; LIU Yuehua; JIN Hongzhong; XU Qiang; LIU Wenjing; LUO Yaping; YANG Hongbo; WANG Tao

doi:10.12376/j.issn.2097-0501.2023.03.014

Journal of Rare Diseases > 2023 > 2(3): 427-431. > DOI: 10.12376/j.issn.2097-0501.2023.03.014

HU Zhonghui, YANG Lu, LIU Yuehua, JIN Hongzhong, XU Qiang, LIU Wenjing, LUO Yaping, YANG Hongbo, WANG Tao. Necrolytic Migratory Erythema—A Case Report of Pancreatic Occupying Lesion[J]. Journal of Rare Diseases, 2023, 2(3): 427-431. DOI: 10.12376/j.issn.2097-0501.2023.03.014

Citation:

PDF (2324 KB)

Necrolytic Migratory Erythema—A Case Report of Pancreatic Occupying Lesion

1.
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
2.
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
3.
Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
4.
Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

National High Level Hospital Clinical Research Funding 2022-PUMCH-A-164

Beijing Natural Science Foundation Z210017

More Information

Corresponding author:
WANG Tao, E-mail: wangtaopumch@126.com
Received Date: July 11, 2022
Accepted Date: September 22, 2022
Available Online: September 08, 2023

Graphical Abstract

Abstract

Abstract

Glucagonoma is a rare neuroendocrine tumor of α cells of the pancreas. The tumor excessively secretes glucagon and causes glucagonoma syndrome.70%-90% of patients with glucagonoma will develop necrolytic migratory erythema (NME). We reported a patient of glucagonoma syndrome who was presented to the dermatology outpatient clinic with a 2-year-history of recurrent erythema and scaling on the skin migrating throughout the body. A skin biopsy was performed and resulting features matched with NME, whilst imaging examinations suggested a soft tissue density tumor present in the tail of the pancreas with somatostatin receptor expression and laboratory tests found an elevated levels of serum glucagon. After the diagnosis was confirmed, the patient was treated with surgical resection of the glucagonoma and the skin eruptions resolved rapidly in 4 days. Meanwhile, we reviewed relevant literature published in recent years and summarized its clinical characteristics in order to improve its understanding by clinicians, including clinical manifestations, laboratory and imaging examinations, diagnosis and treatments.
- necrolytic migratory erythema,
- glucagonoma,
- glucagonoma syndrome,
- pancreatic occupying lesion

FullText(HTML)

References (19)

References

[1]	Luber AJ, Ackerman LS, Culpepper KS, et al. Paediatric necrolytic migratory erythema as a presenting sign of glucagonoma syndrome[J]. Br J Dermatol, 2016, 174(5): 1092-1095. doi: 10.1111/bjd.14298
[2]	Al-Faouri A, Ajarma K, Alghazawi S, et al. Glucagonoma and glucagonoma syndrome: a case report with review of recent advances in management[J]. Case Rep Surg, 2016, 2016: 1484089.
[3]	Wermers RA, Fatourechi V, Wynne AG, et al. The glucagonoma syndrome. Clinical and pathologic features in 21 patients[J]. Medicine (Baltimore), 1996, 75(2): 53-63. doi: 10.1097/00005792-199603000-00002
[4]	Tolliver S, Graham J, Kaffenberger BH. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema[J]. Int J Dermatol, 2018, 57(6): 642-645. doi: 10.1111/ijd.13947
[5]	Daly DM, Thompson B, Low J, et al. Emergency pancreatic resection for glucagonoma associated with severe necrolytic migratory erythema[J]. ANZ J Surg, 2019, 89(5): 599-602. doi: 10.1111/ans.14186
[6]	Remes-Troche JM, García-de-Acevedo B, Zuñiga-Varga J, et al. Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome[J]. J Eur Acad Dermatol Venereol, 2004, 18(5): 591-595. doi: 10.1111/j.1468-3083.2004.00981.x
[7]	Liu JW, Qian YT, Ma DL. Necrolytic migratory erythema[J]. JAMA Dermatol, 2019, 155(10): 1180. doi: 10.1001/jamadermatol.2019.1658
[8]	John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment[J]. J Eur Acad Dermatol Venereol, 2016, 30(12): 2016-2022. doi: 10.1111/jdv.13752
[9]	Compton NL, Chien AJ. A rare but revealing sign: necrolytic migratory erythema[J]. Am J Med, 2013, 126(5): 387-389. doi: 10.1016/j.amjmed.2013.01.012
[10]	Gracia-Darder I, Ramos D, Boix-Vilanova J, et al. Necrolytic migratory erythema associated with painful plantar keratoderma. A new diagnostic clue for this paraneoplastic syndrome?[J]. An Bras Dermatol, 2020, 95(5): 666-668. doi: 10.1016/j.abd.2020.02.011
[11]	Kitamura Y, Sato M, Hatamochi A, et al. Necrolytic migratory erythema without glucagonoma associated with hepatitis B[J]. Eur J Dermatol, 2005, 15(1): 49-51.
[12]	Chiyomaru K, Takai T, Ohashi A, et al. Necrolytic migratory erythema with cholangiocarcinoma: pseudoglucagonoma syndrome[J]. Eur J Dermatol, 2010, 20(2): 238-239. doi: 10.1684/ejd.2010.0878
[13]	Technau K, Renkl A, Norgauer J, et al. Necrolytic migratory erythema with myelodysplastic syndrome without glucagonoma[J]. Eur J Dermatol, 2005, 15(2): 110-112.
[14]	Lobo I, Carvalho A, Amaral C, et al. Glucagonoma syndrome and necrolytic migratory erythema[J]. Int J Dermatol, 2010, 49(1): 24-29. doi: 10.1111/j.1365-4632.2009.04220.x
[15]	Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)[J]. Gut, 2012, 61(1): 6-32. doi: 10.1136/gutjnl-2011-300831
[16]	Zhu WF, Zheng SS. Glucagonoma syndrome with necrolytic migratory erythema as initial manifestation[J]. Hepatobiliary Pancreat Dis Int, 2021, 20(6): 598-600. doi: 10.1016/j.hbpd.2021.09.005
[17]	Wu SL, Bai JG, Xu J, et al. Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor[J]. World J Surg Oncol, 2014, 12: 220. doi: 10.1186/1477-7819-12-220
[18]	Jiménez-Gallo D, Ossorio-García L, de la Varga-Martínez R, et al. Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine[J]. Dermatol Ther, 2017, 30(4). 10.1111/dth. 12498.
[19]	Tremblay C, Marcil I. Necrolytic migratory erythema: a forgotten paraneoplastic condition[J]. J Cutan Med Surg, 2017, 21(6): 559-561. doi: 10.1177/1203475417719051

[1]	XIE Shiyao, LIU Ziyu, LI Shunping. Present Situation and Countermeasures of China′s Legal Responses to Rare Diseases[J]. Journal of Rare Diseases, 2024, 3(3): 405-410. DOI: 10.12376/j.issn.2097-0501.2024.03.021
[2]	DONG Xinran, ZHOU Wenhao. Work Plan for the Clinical Utility & Usefulness Measures Working Group of Medical Genome Committee[J]. Journal of Rare Diseases, 2024, 3(3): 304-309. DOI: 10.12376/j.issn.2097-0501.2024.03.005
[3]	DONG Xinran, ZHOU Wenhao. The China Neonatal Genomes Project(CNGP): New Advances in the Cohort Study of Genotype and Phenotype of Rare Diseases[J]. Journal of Rare Diseases, 2024, 3(3): 280-287. DOI: 10.12376/j.issn.2097-0501.2024.03.002
[4]	LI Kexin, CHEN Jingdan, ZHANG Dingding, GUO Wudong, ZHENG Jiayin, LI Linkang, ZHAO Kun, ZHANG Shuyang. Thoughts on Selection of Rare Diseases and Prioritized Research Topics[J]. Journal of Rare Diseases, 2024, 3(2): 269-274. DOI: 10.12376/j.issn.2097-0501.2024.02.018
[5]	WANG Shaohong, LIU Xin, LIU Qingyang, TANG Yan, ZHANG Bo. Overview and Analysis of Rare Disease Drugs Approved for Market in China, the United States, the European Union, and Japan in 2023[J]. Journal of Rare Diseases, 2024, 3(2): 202-213. DOI: 10.12376/j.issn.2097-0501.2024.02.008
[6]	LIU Qingyang, LIU Xin, ZUO Wei, WANG Shaohong, ZHANG Bo, ZHANG Shuyang. Study on Drug List and Accessibility of Rare Diseases Based on the China′s Second List of Rare Diseases[J]. Journal of Rare Diseases, 2024, 3(2): 195-201. DOI: 10.12376/j.issn.2097-0501.2024.02.007
[7]	LI Kexin, ZHAO Kun, ZHENG Jiayin, YANG Yuqi, LI Linkang. Current Status of Drug Development and Implementation for Diseases Included in the Second Catalog of Rare Diseases[J]. Journal of Rare Diseases, 2023, 2(4): 596-601. DOI: 10.12376/j.issn.2097-0501.2023.04.015
[8]	ZHANG Xueyi, SUN Bo, CHEN Guilin, HU Ge, LI Qing, QIU Guixing. Computer Vision in Medical Imaging and its Impact on the Rare Musculoskeletal Diseases[J]. Journal of Rare Diseases, 2023, 2(4): 589-595. DOI: 10.12376/j.issn.2097-0501.2023.04.014
[9]	TAO Libo, WANG Fangxu, JIA Fanghong, YANG Yulin, ZHENG Jiayin, ZHANG Shuyang. The Exploration and Analysis of Constructing a Multiple Health Security System for Rare Diseases in China[J]. Journal of Rare Diseases, 2023, 2(1): 135-142. DOI: 10.12376/j.issn.2097-0501.2023.01.019
[10]	ZHANG Haiqin, LI Shunping, FENG Junchao. Application Status, Problems and Suggestions of Commerical Health Insurance in Medical Security for Rare Dsieases in China[J]. Journal of Rare Diseases, 2022, 1(1): 84-88. DOI: 10.12376/j.issn.2097-0501.2022.01.014

Cited By

Get Citation

PDF

XML

Article views (146) PDF downloads (32)

Turn off MathJax

Article Contents

Abstract

References

Necrolytic Migratory Erythema—A Case Report of Pancreatic Occupying Lesion

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content